Tenderwize
Retour à la recherche

Open house discount agreements for iron(III)hydroxide-polymaltose complex, ATC B03AC01

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline May 05, 2027 · 249 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Eisen(III)hydroxid-Polymaltose-Komplex, ATC B03AC01

50/100

Score d'opportunité

PromisingLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

No guaranteed purchase volume or minimum order quantity; revenue depends on actual prescriptions and market share.

Open-house agreements may be overridden by future formal framework contracts (bundesweit oder landesspezifisch) for the...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Supply of pharmaceutical products containing iron(III)hydroxide-polymaltose complex (ATC B03AC01) to AOK Bayern insured persons
  • Conclusion of non-exclusive discount agreements (rabattverträge) under §130a(8) SGB V
Afficher le résumé complet

The AOK Bayern (Bavaria Health Insurance) is conducting an open-house model for non-exclusive discount agreements on pharmaceutical products containing iron(III)hydroxide-polymaltose complex (ATC B03AC01) under §130a(8) SGB V. This is not a typical procurement procedure; any interested pharmaceutical company meeting eligibility criteria can sign identical, non-negotiable agreements. Contracts have a fixed end date of 30 June 2027, with possible start from 1 July 2025. The open-house is open until 5 May 2027. No estimated contract value is provided. The process is governed by German social law, not procurement law. Submission can be in paper form (hand-signed) or electronically with a qualified electronic signature. Only pharmaceutical companies can participate.

Risques

No guaranteed purchase volume or minimum order quantity; revenue depends on actual prescriptions and market share.

Open-house agreements may be overridden by future formal framework contracts (bundesweit oder landesspezifisch) for the...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Only pharmaceutical companies (pharmazeutische Unternehmen) can participate

Administrative

  • Submission of signed contract, completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
  • Hand-signed paper documents in duplicate OR electronically with qualified electronic signature via the communication area of the dtvp portal

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria; participation is open to all qualified pharmaceutical companies.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house discount agreements for iron(III)hydroxide-polymaltose complex, ATC B03AC01

Non-exclusive discount agreements for the active ingredient iron(III)hydroxide-polymaltose complex (ATC B03AC01). Contracts are identical for all participants, no individual negotiation. Performance location: Bavaria, Germany. Contract period: 1 July 2025 to 30 June 2027. Early termination possible with one month notice. Agreements automatically superseded if a nationwide or state-specific framework discount contract for the same active ingredient is concluded via a formal procedure.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Jun 2025 - Jun 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria; participation is open to all qualified pharmaceutical companies.

Date limite

Deadline May 05, 2027

Détails de la procédure

Date de publication
15 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
315689-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30